Curi Bio and Cook MyoSite Announce Strategic Partnership

Through this collaboration, portfolio company Curi Bio will integrate its versatile Mantarry 3D tissue engineering platform—compatible with diverse biological models and assays delivering clinically relevant functional outputs—with primary human myoblasts and fibro-adipogenic progenitor cells (FAPs) provided by Cook MyoSite. 

This integration will produce sophisticated, physiologically relevant tissue models, bridging critical research gaps in conditions such as sarcopenia (age-related muscle atrophy), diabetes, obesity, neuromuscular disorders, and diseases responsive to GLP-1 therapies.